These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20395392)

  • 1. An unusual cause of multiple cerebral hemorrhages: drotrecogin alpha (activated protein C).
    Algin O; Ceylan G; Kilic E
    AJNR Am J Neuroradiol; 2011 May; 32(5):E85-6. PubMed ID: 20395392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
    Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
    Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Re-administration of drotrecogin alfa activated in a patient with episodes of severe sepsis].
    Verdú MT; Sánchez OJ
    Rev Esp Anestesiol Reanim; 2007 Dec; 54(10):637-8. PubMed ID: 18201006
    [No Abstract]   [Full Text] [Related]  

  • 5. Corticosteroids and human recombinant activated protein C for septic shock.
    Colin G; Annane D
    Clin Chest Med; 2008 Dec; 29(4):705-12, x. PubMed ID: 18954704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
    Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
    Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
    N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis.
    Shorr AF; Williams MD
    Thromb Haemost; 2009 Jan; 101(1):139-44. PubMed ID: 19132200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New additions to the intensive care armamentarium.
    Rice TW; Bernard GR
    Drugs Today (Barc); 2004 Feb; 40(2):157-70. PubMed ID: 15045037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated protein C for sepsis.
    Toussaint S; Gerlach H
    N Engl J Med; 2009 Dec; 361(27):2646-52. PubMed ID: 20042756
    [No Abstract]   [Full Text] [Related]  

  • 15. Bleeding complications with Drotrecogin alfa activated (Xigris): a retrospective review of 31 operative and 68 non-operative patients with severe sepsis.
    Taylor BJ; Lee SJ; Waxman K
    Am Surg; 2008 Oct; 74(10):898-901. PubMed ID: 18942609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
    Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
    Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of septic shock and use of drotrecogin alfa (activated) in children.
    Marraro GA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):769-72. PubMed ID: 19735218
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
    McCoy C; Matthews SJ
    Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.